<DOC>
	<DOCNO>NCT00008801</DOCNO>
	<brief_summary>The broad , long-term goal proposal improve result applicability islet allotransplantation early course type 1 diabetes administration selective short-term immunotherapy . More specifically , objective study conduct open-labeled , one-year follow-up Phase I/II study patient surgical type 1 diabetes determine safety , tolerability , immune activity , pharmacokinetics hOKT3gamma1 ( Ala-ala ) administration prevention autoimmune destruction rejection allogeneic islet transplant .</brief_summary>
	<brief_title>hOKT3gamma1 ( Ala-Ala ) Prevention Human Islet Allograft Failure</brief_title>
	<detailed_description>Adverse event monitor record throughout first year post-transplant . The proportion surgical type 1 diabetic subject receive islet allotransplant achieve maintain full partial islet graft function first year post-transplant determine assess efficacy hOKT3gamma1 ( Ala-ala ) administration . Successful completion propose clinical trial increase understand safety , efficacy underlying mechanism selective immunotherapy anti-CD3 monoclonal antibody hOKT3gamma1 ( Ala-ala ) maximization engraftment functional survival allogeneic human islets surgical type 1 diabetic recipient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetes Mellitus , Experimental</mesh_term>
	<criteria>Inclusion : Primary islet allotransplant surgical type 1 diabetes mellitus , complicate sign symptom persist despite intensive effort make close cooperation diabetes care team Age 18 old must give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>